Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Brokerages

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has earned a consensus rating of "Buy" from the eight ratings firms that are currently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $10.00.

ACRS has been the subject of a number of research analyst reports. StockNews.com cut Aclaris Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, February 8th. HC Wainwright reissued a "buy" rating and set a $16.00 target price (down previously from $20.00) on shares of Aclaris Therapeutics in a research note on Wednesday. Cantor Fitzgerald initiated coverage on shares of Aclaris Therapeutics in a research note on Tuesday, March 18th. They issued an "overweight" rating on the stock. Finally, Scotiabank decreased their price target on shares of Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating on the stock in a report on Friday, May 9th.

Institutional Trading of Aclaris Therapeutics

Hedge funds have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. bought a new position in Aclaris Therapeutics in the 4th quarter valued at approximately $23,876,000. Vivo Capital LLC acquired a new position in Aclaris Therapeutics in the 4th quarter valued at approximately $22,044,000. RA Capital Management L.P. bought a new position in shares of Aclaris Therapeutics during the fourth quarter valued at $11,573,000. Rock Springs Capital Management LP lifted its holdings in shares of Aclaris Therapeutics by 125.3% during the fourth quarter. Rock Springs Capital Management LP now owns 6,204,309 shares of the biotechnology company's stock worth $15,387,000 after purchasing an additional 3,450,814 shares during the period. Finally, Janus Henderson Group PLC acquired a new position in shares of Aclaris Therapeutics during the fourth quarter worth $6,985,000. 98.34% of the stock is owned by institutional investors and hedge funds.

Aclaris Therapeutics Stock Up 7.4%

Shares of Aclaris Therapeutics stock opened at $1.31 on Friday. Aclaris Therapeutics has a 12-month low of $0.95 and a 12-month high of $5.17. The company has a market capitalization of $141.85 million, a price-to-earnings ratio of -2.52 and a beta of 0.42. The firm's 50-day moving average price is $1.36 and its two-hundred day moving average price is $2.23.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.07. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. On average, sell-side analysts expect that Aclaris Therapeutics will post -0.82 earnings per share for the current year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.